Discontinuation of angiotensin-converting enzyme inhibitors: A cohort study

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 3, 2012, Pages 335-341

  Wong, M C S ^a   Lau, R K C ^b   Jiang, J Y ^c   Griffiths, S M ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b HONG KONG SHUE YAN UNIVERSITY   (Hong Kong)

^c PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

angiotensin converting enzyme inhibitors; associated factors; Chinese; discontinuation

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHINESE; CLINICAL PRACTICE; COMORBIDITY; CONSULTATION; DATA BASE; DRUG WITHDRAWAL; FAMILY MEDICINE; FEMALE; HONG KONG; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTIPLE REGRESSION; PREDICTOR VARIABLE; PRESCRIPTION; PRIMARY MEDICAL CARE; SEX DIFFERENCE; URBAN RURAL DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DRUG PRESCRIPTIONS; FAMILY PRACTICE; FEMALE; HEALTH STATUS; HONG KONG; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; RISK; RURAL HEALTH; SEX CHARACTERISTICS; SOCIOECONOMIC FACTORS; URBAN HEALTH; YOUNG ADULT;

EID: 84861333404     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01300.x     Document Type: Article

References (46)

1. National Collaborating Centre for Chronic Conditions (2006) Hypertension: management in adults in primary care: pharmacological update. London: Royal College of Physicians.
2. Chobanian AV, Bakris GL, Black HR, et al. (2003) National Heart, Lung, and Blood Institute Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC-7 report. JAMA, 289, 2560-2572.
3. Blood Pressure Lowering Treatment Trialists' Collaboration (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet, 356, 1955-1964.
4. Wing LMH, Reid CM, Ryan P, et al. (2003) A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. New England Journal of Medicine, 348, 583-592.
5. Mancia G, De Backer G, Dominiczak A, et al. (2007) 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 28, 1462-1536.
6. Whitworth JA, (2003) World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension, 21, 1983-1992.
7. Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. (2005) Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. Journal of Hypertension, 23, 2093-2100.
8. Bloom BS, (1998) Continuation of initial antihypertensive medication after 1 year of therapy. Clinical Therapeutics, 20, 671-681.
9. Bourgault C, Sénécal M, Brisson M, Marentette MA, Grégoire JP, (2005) Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. Journal of Human Hypertension, 19, 607-613.
10. Degli Esposti L, Degli Esposti E, Valpiani G, et al. (2002) A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clinical Therapeutics 24: 1347-1357; discussion 1346.
11. Degli Esposti E, Sturani A, Di Martino M, et al. (2002) Long-term persistence with antihypertensive drugs in new patients. Journal of Human Hypertension, 16, 439-444.
12. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ, (2001) Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist Losartan versus other antihypertensive drug classes. Clinical Therapeutics, 23, 1999-2010.
13. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A, (2005) Rate and determinants of 10-year persistence with antihypertensive drugs. Journal of Hypertension, 23, 2101-2107.
14. Corrao G, Zambon A, Parodi A, et al. (2008) Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. Journal of Hypertension, 26, 819-824.
15. Burke TA, Sturkenboom MC, Lu S, Wenworth CE, Lin Y, Rhoads GG, (2006) Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. Journal of Hypertension, 24, 1193-1200.
16. Ong HT, (2009) Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection? Journal of the American Board of Family Medicine, 22, 686-697.
17. Wong MCS, Jiang JY, Lam AT, Fung H, Giffiths S, Mercer SW, (2008) Patterns of antihypertensive prescribing, discontinuation and switching among a Hong Kong Chinese population from over one million prescriptions. Journal of Human Hypertension, 22, 714-716.
18. Wong MCS, Jiang JY, Gibbs T, Griffiths SM, (2009) Factors associated with antihypertensive drug discontinuation among Chinese patients: a cohort study. American Journal of Hypertension, 22, 802-810.
19. Wong MCS, (2008) Short- and long-term discontinuation patterns of commonly prescribed antihypertensive drugs among a Chinese population: cohort study. Journal of Human Hypertension, 22, 435-437.
20. Mann JFE, Schmeider RE, McQueen M, et al. (2008) Renal outcomes with Telmisartan, Ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet, 372, 547-553.
21. Rogers PG, Bullman WR, (1995) Prescription medicine compliance: a review of the baseline of knowledge. A report of the national council on patient information and education. Journal of Pharmacoepidemiology, 3, 3-36.
22. Martino MD, Veronesi C, Esposti LD, et al. (2008) Adherence to antihypertensive drug treatment and blood pressure control: a real practice analysis in Italy. Journal of Human Hypertension, 22, 51-53.
23. McAlister FA, Lewanczuk R, (1994) Hypertensive crisis after discontinuation of angiotensin-converting enzyme inhibitor. Lancet, 344, 1502.
24. Brown MJ, (2006) Hypertension and ethnic group. BMJ, 332, 833-836.
25. Kola LD, Sumaili EK, Krzesinski JM, (2009) How to treat hypertension in blacks: review of the evidence. Acta Clinica Belgica, 64, 466-476.
26. Wong MCS, Jiang JY, Griffiths S, (2010) Switching of antihypertensive drugs among 93,286 Chinese patients: a cohort study. Journal of Human Hypertension, 24, 669-677.
27. Wong MCS, Jiang JY, Lam AT, Fung H, Griffiths S, Mercer SW, (2008) Health services research in the public healthcare system in Hong Kong: an analysis of over 1 million antihypertensive prescriptions between 2004-2007 as an example of the potential and pitfalls of using routinely collected electronic patient data. BMC Health Services Research, 8, 138.
28. HA and Clinical Research-Support, Output and Direction. Available at: (accessed 20 April 2010).
29. Population by census (2006) Hong Kong Special Administrative Region, China. Available at: (accessed 20 April, 2010).
30. Katz MH, (2006) Multivariable analysis: a practical guide for clinicians, 2nd edn. Cambridge: Cambridge University Press, 69.
31. Wong MC, Jiang JY, Su X, Wang H, Tang JL, Griffiths SM, (2010) Individuals at risk of beta-blocker discontinuation: a cohort study in 19,177 Chinese patients. Clinical Research in Cardiology, 99, 277-284.
32. Wong MCS, Jiang Y, Griffiths S, (2009) Factors associated with compliance, discontinuation and switching of calcium channel blockers in 20,156 Chinese patients. American Journal of Hypertension, 22, 904-910.
33. Wong MCS, Jiang Y, Griffiths S, (2010) Adherence to combination therapy among ethnic Chinese patients: a cohort study. Hypertension Research, 33, 416-421.
34. Tu K, Campbell NRC, Duong-Hua M, McAlister FA, (2005) Hypertension management in the elderly has improved: Ontario prescribing trends, 1994 to 2002. Hypertension, 45, 1113-1118.
35. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD, (1999) Persistence with treatment for hypertension in actual practice. CMAJ, 160, 31-37.
36. Billups SJ, Malone DC, Carter BL, (2000) The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs. Pharmacotherapy, 20, 941-949.
37. Vaur L, Vaisse B, Genes N, Elkik F, Legrand C, Poggi L, (1999) Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large-scale trial. American Journal of Hypertension, 12, 374-380.
38. Falconnet C, Murielle B, Bovet P, Maillard M, Burnier M, (2004) Gender difference in the response to an angiotensin-converting enzyme inhibitor and a diuretic in hypertensive patients of African descent. Journal of Hypertension, 22, 1213-1220.
39. Carter BL, (2007) Adherence, quality of life, cost effectiveness, and the role of the pharmacist. In:, Lip GYH, Hall JE, eds. Comprehensive hypertension, chapter 92, Maryland Heights: Mosby Inc., 1119-1127.
40. Elliott WJ, (1996) Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clinical Pharmacology and Therapeutics, 60, 582-588.
41. Dicpinigaitis PV, (2006) Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest, 129, 169S-173S.
42. Byrd JB, Adam A, Brown NJ, (2006) Angiotensin-converting enzyme inhibitor associated angioedema. Immunology and Allergy Clinics of North America, 26, 725-737.
43. Miller NH, Hill M, Kottke T, Ockene IS, (1997) The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation, 95, 1085-1090.
44. Schroeder K, Fahey T, Ebrahim S, (2004) How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Archives of Internal Medicine, 164, 722-732.
45. Sleight P, (2009) Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor. Journal of Hypertension, 27, S23-S29.
46. Beltrami L, Zingale LC, Carugo S, Cicardi M, (2006) Angiotensin- converting enzyme inhibitor-related angioedema: how to deal with it. Expert Opinion on Drug Safety, 5, 643-649.